Evidence map›Paper›PMID 37287871›Full record

ArticleEClinicalMedicine2023

Effect of the relationship between anaemia and systemic inflammation on the risk of incident tuberculosis and death in people with advanced HIV: a sub-analysis of the REMEMBER trial.

Mariana Araújo-Pereira, Sonya Krishnan, Padmini Salgame, Yukari C Manabe, Mina C Hosseinipour, Gregory Bisson, Damocles Patrice Severe, Vanessa Rouzier, Samantha Leong, Vidya Mave and 13 more

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 9 countries.

Mariana Araújo-PereiraInstituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Sonya KrishnanDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Padmini SalgameDepartment of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Yukari C ManabeDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mina C HosseinipourDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gregory BissonUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Damocles Patrice SevereLes Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince HT6110, Haiti.
Vanessa RouzierLes Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince HT6110, Haiti.
Samantha LeongDepartment of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, USA.
Vidya MaveBJ Medical College Clinical Research Site, Pune, India.
Fredrick Kipyego SaweHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Abraham M SiikaDepartment of Medicine, School of Medicine, Moi University, Eldoret, Kenya.
Cecilia KanyamaUniversity of North Carolina Project, Kamazu Central Hospital, Lilongwe, Malawi.
Sufia S DadabhaiJohns Hopkins Bloomberg School of Public Health, Blantyre, Malawi.
Javier R LamaAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Javier Valencia-HuamaniAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Sharlaa Badal-FaesenClinical HIV Research Unit, School of Clinical Medicine, University of Witwatersrand, Johannesburg, South Africa.
Umesh Gangaram LallooMorningside Mediclinic, Sandton, Johannesburg, South Africa.
Kogieleum NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal Nelson R Mandela School of Medicine, Durban, South Africa.
Lerato MohapiSchool of Clinical Medicine, University of Witwatersrand, Johannesburg, South Africa.
Cissy KityoHIV Medicine, Joint Clinical Research Centre, Kampala, Uganda.
Bruno B AndradeInstituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Amita GuptaDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USAsociación Civil Impacta Salud y Educación · PEGheskio Centers · HTRutgers, The State University of New Jersey · USUniversidade Federal da Bahia · BRUniversity of the Witwatersrand · ZAB. J. Medical College & Sassoon Hospital · INCentre for the AIDS Programme of Research in South Africa · ZAHenry M. Jackson Foundation · USJoint Clinical Research Centre · UGKamuzu Central Hospital · MWMoi University · KEUniversity of Malawi · MWUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
The Malawi Clinical Trials UnitUM1AI069518 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JACKY M JENNINGS, TAHA E TAHA · 2012 to 2026
$43.8M
Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
United States Military HIV Research Program (MHRP) Clinical Trials UnitUM1AI108568 · NIAID · WALTER REED ARMY INSTITUTE OF RESEARCH · PI Julie A. Ake, Merlin L Robb · 2014 to 2026
$24.3M
Medical Research Council MC_PC_16022NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI069518NIAID NIH HHS UM1 AI108568
6 · The paper itself

Abstract

Background: Tuberculosis (TB) is an infectious morbidity that commonly occurs in people living with HIV (PWH) and increases the progression of HIV disease, as well as the risk of death. Simple markers of progression are much needed to identify those at highest risk for poor outcome. This study aimed to assess how baseline severity of anaemia and associated inflammatory profiles impact death and the incidence of TB in a cohort of PWH who received TB preventive therapy (TPT). Methods: This study is a secondary posthoc analysis of the AIDS Clinical Trials Group A5274 REMEMBER clinical trial (NCT0138008), an open-label randomised clinical trial of antiretroviral-naïve PWH with CD4 <50 cells/μL, performed from October 31, 2011 to June 9, 2014, from 18 outpatient research clinics in 10 low- and middle-income countries (Malawi, South Africa, Haiti, Kenya, Zambia, India, Brazil, Zimbabwe, Peru, and Uganda) who initiated antiretroviral therapy and either isoniazid TPT or 4-drug empiric TB therapy. Plasma concentrations of several soluble inflammatory biomarkers were measured prior to the commencement of antiretroviral and anti-TB therapies, and participants were followed up for at least 48 weeks. Incident TB or death during this period were primary outcomes. We performed multidimensional analyses, logistic regression analyses, survival curves, and Bayesian network analyses to delineate associations between anaemia, laboratory parameters, and clinical outcomes. Findings: Of all 269 participants, 76.2% (n = 205) were anaemic, and 31.2% (n = 84) had severe anaemia. PWH with moderate/severe anaemia exhibited a pronounced systemic pro-inflammatory profile compared to those with mild or without anaemia, hallmarked by a substantial increase in IL-6 plasma concentrations. Moderate/severe anaemia was also associated with incident TB incidence (aOR: 3.59, 95% CI: 1.32-9.76, p = 0.012) and death (aOR: 3.63, 95% CI: 1.07-12.33, p = 0.039). Interpretation: Our findings suggest that PWH with moderate/severe anaemia display a distinct pro-inflammatory profile. The presence of moderate/severe anaemia pre-ART was independently associated with the development of TB and death. PWH with anaemia should be monitored closely to minimise the occurrence of unfavourable outcomes. Funding: National Institutes of Health.

Indexed as

AnaemiaDeathHaemoglobinHIVIncident TBInflammationSystemic inflammationTuberculosis

Identifiers

PMID37287871
PMCPMC10242630
OpenAlexW4379184166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.